TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27538776

Group type: EXPERIMENTAL
Intervention: Single dose intraoperative electron radiotherapy (IOERT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Whole breast irradiation (WBI)
Number of subjects: 71
Study: 24696094

Group type: EXPERIMENTAL
Intervention: Bitopertin 10 mg/d
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Bitopertin 30 mg/d
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study: 22324890

Group type: COMPARATOR
Intervention: GlideScope videolaryngoscope
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Shikani optical stylet
Number of subjects: 60
Study: 20357295

Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin (300-450 mg/d)
Number of subjects: 0
Study: 18612570

Group type: EXPERIMENTAL
Intervention: Categorical BAC information from the saliva test
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Precise (three-digit) BAC information from the breath alcohol analyzer
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Categorical BAC information corroborated by a calibrated police breath alcohol analyzer
Number of subjects: 959

Group type: COMPARATOR
Intervention: Control condition (no BAC feedback provided)
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: All BAC information conditions
Number of subjects: 959
Study: 15891317

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) and Propofol
Number of subjects: 89
Study: 12017347

Group type: EXPERIMENTAL
Intervention: Oral eletriptan (1.5-30 mg or 30-120 mg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intravenous eletriptan (1.67-50 microg/kg or 50-102 microg/kg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Oral eletriptan
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Oral eletriptan doses > or = 60 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Eletriptan
Number of subjects: 55
Study: 9915433

Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy
Number of subjects: 365

Group type: COMPARATOR
Intervention: Open prostatectomy
Number of subjects: 365
Study: 7771032

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (EA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Combined epidural and general anesthesia (EG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 100
Study: 2182732

Group type: EXPERIMENTAL
Intervention: Single-dose trimethoprim treatment
Number of subjects: 613

Group type: COMPARATOR
Intervention: 7-day trimethoprim treatment
Number of subjects: 613
Study: 870566

Group type: EXPERIMENTAL
Intervention: Influenza A/England/42/72 (H3N2) virus vaccine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31264391

Group type: EXPERIMENTAL
Intervention: temporally distanced meaning making
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: spatially distanced meaning making
Number of subjects: 136

Group type: COMPARATOR
Intervention: self-immersed meaning making
Number of subjects: 136
Study: 28610561

Group type: EXPERIMENTAL
Intervention: Blended care (Act and Feel treatment: an eight-week web-based program based on behavioral activation with integrated monitoring of depressive symptomatology and automatized feedback)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (standard treatment by GPs or MHWs)
Number of subjects: 300
Study: 26293121

Group type: EXPERIMENTAL
Intervention: Stapedotomy surgery
Number of subjects: 133
Study: 23549826

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20% albumin
Number of subjects: 0
Study: 21623642

Group type: EXPERIMENTAL
Intervention: Irbesartan (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No irbesartan (n=50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Age (as a variable)
Number of subjects: 100
Study: 19637834

Group type: EXPERIMENTAL
Intervention: Naftalan application
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Therapeutic mud application
Number of subjects: 82

Group type: COMPARATOR
Intervention: No physical factors (Control)
Number of subjects: 82
Study: 16698485

Group type: EXPERIMENTAL
Intervention: Crystalens IOL
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard monofocal IOL
Number of subjects: 112
Study: 15526237

Group type: EXPERIMENTAL
Intervention: Candesartan (target dose 32 mg once daily)
Number of subjects: 0
Study: 11309632

Group type: EXPERIMENTAL
Intervention: Early insertion of tympanostomy tubes
Number of subjects: 429

Group type: COMPARATOR
Intervention: Delayed insertion of tympanostomy tubes
Number of subjects: 429
Study: 9312651

Group type: EXPERIMENTAL
Intervention: Welders exposed to welding fumes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Welders who smoke
Number of subjects: 20
Study: 7685221

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (activated clotting time, > 180 sec)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Full-dose heparin (activated clotting time, > 480 sec) with high-dose aprotinin
Number of subjects: 15
Study: 3319461

Group type: EXPERIMENTAL
Intervention: 5-ASA suppositories, 500 mg t.i.d. for 6 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 27
Study: 29530060

Group type: EXPERIMENTAL
Intervention: Guideline and policy implementation strategies
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 121
Study: 26285003

Group type: EXPERIMENTAL
Intervention: Intervention (INT): One-time consultation with a sleep specialist
Number of subjects: 137
Study: 25057103

Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet during pregnancy
Number of subjects: 460

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 460
Study: 22436400

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs) with 30 μg of ethinylestradiol (EE)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs) with 15 μg of ethinylestradiol (EE)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Nonusers of COCs
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs)
Number of subjects: 84
Study: 20701812

Group type: EXPERIMENTAL
Intervention: Quit with Practice Nurse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quitline referral
Number of subjects: 0

Group type: COMPARATOR
Intervention: GP usual care
Number of subjects: 0
Study: 19641768

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (In-ovation brackets)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional preadjusted straight wire brackets
Number of subjects: 20
Study: 16162943

Group type: EXPERIMENTAL
Intervention: 10 mg/day ezetimibe combined with 25 g/day spread containing 2.0 g of plant sterols
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 25 g/day spread containing 2.0 g of plant sterols
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10 mg/day ezetimibe
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment consisting of 25 g/day control spread
Number of subjects: 40
Study: 12578865

Group type: EXPERIMENTAL
Intervention: Plasma hs-CRP levels in CAD patients
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Plasma adiponectin concentrations in CAD patients
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: CRP mRNA levels in human adipose tissue
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: CRP mRNA level in white adipose tissue of adiponectin deficient mice
Number of subjects: 101
Study: 10319771

Group type: EXPERIMENTAL
Intervention: 0.9% saline infusion (30 ml x kg(‐1) x h(‐1))
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lactated Ringer's solution infusion (30 ml x kg(‐1) x h(‐1))
Number of subjects: 24
Study: 8907138

Group type: EXPERIMENTAL
Intervention: Graphical display of pain levels on bedside wall charts
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard periodic pain assessments without graphical display
Number of subjects: 78
Study: 1862584

Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam daily for ten days
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: 20 mg piroxicam daily for ten days
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo for ten days
Number of subjects: 212
Study: 6134861

Group type: EXPERIMENTAL
Intervention: Metipranolol 0.3%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol 0.25%
Number of subjects: 0
Study: 31816446

Group type: EXPERIMENTAL
Intervention: Ustekinumab (130 mg intravenous induction)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Ustekinumab (90 mg subcutaneous maintenance every 8 weeks)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Ustekinumab (90 mg subcutaneous maintenance every 12 weeks)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 30797387

Group type: EXPERIMENTAL
Intervention: Intervention group (providers attended three group training sessions to enhance communication skills)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 418
Study: 28372596

Group type: EXPERIMENTAL
Intervention: Ketamine (0.8 mg/kg administered intravenously over 40 minutes) plus manualised psychological therapy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ketamine (0.8 mg/kg administered intravenously over 40 minutes) plus alcohol education control
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (50 ml saline 0.9% IV over 40 minutes) plus manualised psychological therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (50 ml saline 0.9% IV over 40 minutes) plus alcohol education control
Number of subjects: 96
Study: 25943205

Group type: EXPERIMENTAL
Intervention: Nasal and oropharyngeal swabs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal swabs alone
Number of subjects: 0
Study: 23177356

Group type: EXPERIMENTAL
Intervention: Longitudinal method
Number of subjects: 57

Group type: COMPARATOR
Intervention: Transverse method
Number of subjects: 57
Study: 20970888

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg IV midazolam
Number of subjects: 182

Group type: COMPARATOR
Intervention: 1.5 mg/kg IV ketamine
Number of subjects: 182

Group type: COMPARATOR
Intervention: 4 mg/kg IM ketamine
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 20084738

Group type: EXPERIMENTAL
Intervention: Avon's SS220 Spray
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Avon's SS220 Lotion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bayrepel Lotion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SC Johnson's Autan Bayrepel Lotion
Number of subjects: 12

Group type: COMPARATOR
Intervention: N,N‐diethyl‐3‐methyl‐benzamide (deet)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Null repellent (no repellent at all)
Number of subjects: 12
Study: 17132121

Group type: EXPERIMENTAL
Intervention: Vibration (compression + oscillation)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Compression alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oscillation alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Passive expiration alone
Number of subjects: 10
Study: 15367257

Group type: EXPERIMENTAL
Intervention: Survival estimates derived from the CAPRIE trial data
Number of subjects: 50000

Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 50000

Group type: EXPERIMENTAL
Intervention: Subsequent events
Number of subjects: 50000

Group type: EXPERIMENTAL
Intervention: Disease in multiple vascular beds
Number of subjects: 50000
Study: 11413428

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (no EACA)
Number of subjects: 59
Study: 9135928

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 14
Study: 8124045

Group type: EXPERIMENTAL
Intervention: Monotherapy with antibiotics
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combination of clindamycin with sulfamethoxydiazine and/or pyrimethamine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Monotherapy with clindamycin alone
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combination of clindamycin and pyrimethamine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Any therapeutic concept used
Number of subjects: 75
Study: 2887327

Group type: EXPERIMENTAL
Intervention: Flumazenil (up to 1 mg, intravenous administration)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29970059

Group type: EXPERIMENTAL
Intervention: 70 mg of alendronate sodium and 5600 IU of vitamin D3 (ALN/D5600)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Calcitriol (0.25 μg daily)
Number of subjects: 219
Study: 28400148

Group type: EXPERIMENTAL
Intervention: Topical betulin gel (TBG) consisting of 10% birch bark extract and 90% sunflower oil
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard of care (a non-adhesive moist wound dressing)
Number of subjects: 219
Study: 26270686

Group type: EXPERIMENTAL
Intervention: Micafungin (100 mg/d)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Positive (1,3)-β-d-glucan (ßDG) result
Number of subjects: 241
Study: 24041914

Group type: EXPERIMENTAL
Intervention: Intravenous 0.5 ml Optison
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous 0.5 ml placebo (5% dextrose)
Number of subjects: 30
Study: 21420281

Group type: EXPERIMENTAL
Intervention: Intervention based on selecting participants with high population attributable fraction (AF(p))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional high risk/high response approach to trial design
Number of subjects: 0
Study: 18667790

Group type: EXPERIMENTAL
Intervention: High resolution computed tomography (HRCT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 30
Study: 16642229

Group type: EXPERIMENTAL
Intervention: Closed pleura (CP) group, n=120
Number of subjects: 240

Group type: COMPARATOR
Intervention: Opened pleura (OP) group, n=120
Number of subjects: 240
Study: 12707240

Group type: EXPERIMENTAL
Intervention: Hospital-based cardiac rehabilitation (Hosp-CR)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation (Home-CR)
Number of subjects: 270

Group type: COMPARATOR
Intervention: No cardiac rehabilitation (Control)
Number of subjects: 270
Study: 11899644

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with hematopoietic stem-cell transplantation (HDC/HSCT)
Number of subjects: 0
Study: 8659770

Group type: EXPERIMENTAL
Intervention: Meperidine 0.1%
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Meperidine 0.1% with bupivacaine 0.1%
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Meperidine 0.1% with bupivacaine 0.01%
Number of subjects: 66
Study: 1388643

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) at 150 mg daily
Number of subjects: 5

Group type: COMPARATOR
Intervention: Cocaine doses (0.125 to 0.5 mg/kg)
Number of subjects: 5
Study: 2932833

Group type: EXPERIMENTAL
Intervention: Doppler ultrasonic bubble detection
Number of subjects: 83
Study: 31099330

Group type: EXPERIMENTAL
Intervention: Gentamicin 240 mg (single intramuscular injection)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Ceftriaxone 500 mg (single intramuscular injection)
Number of subjects: 720
Study: 28410283

Group type: EXPERIMENTAL
Intervention: Acriva Reviol MFM 613 IOL
Number of subjects: 30

Group type: COMPARATOR
Intervention: AcrySof ReSTOR SN6AD1 IOL
Number of subjects: 30
Study: 26827702

Group type: EXPERIMENTAL
Intervention: Human recombinant erythropoietin (10 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (10 patients)
Number of subjects: 20
Study: 24090124

Group type: EXPERIMENTAL
Intervention: Teflon infusion set
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Steel infusion set
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall (both types)
Number of subjects: 20
Study: 22527351

Group type: EXPERIMENTAL
Intervention: Lersivirine 1,000 mg QD with midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lersivirine 1,000 mg QD with oral contraceptives (ethinylestradiol and levonorgestrel)
Number of subjects: 0
Study: 20113698

Group type: EXPERIMENTAL
Intervention: Sesame oil (oral administration)
Number of subjects: 64
Study: 17684125

Group type: EXPERIMENTAL
Intervention: 201L allele of S201L (TT versus CC)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: 201L allele of S201L (TC versus CC)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: 277E allele of K277E (GG versus AA)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: 277E allele of K277E (GA versus AA)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: TGTGCG haplotype of six informative single nucleotide polymorphisms
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Regular ibuprofen users homozygous for the variant allele at either M9V or D175G
Number of subjects: 725
Study: 16275814

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (low, medium, and high doses ranging from 7.5 mg/d to 50.0 mg/d)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 11902618

Group type: EXPERIMENTAL
Intervention: Moderate disconfirmers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extreme disconfirmers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate disconfirmers encountered before stereotype is well-established
Number of subjects: 0
Study: 10202979

Group type: EXPERIMENTAL
Intervention: Aberrant expression of nitric oxide synthase III (NOS III) gene and neuritic sprouting in neurodegenerative diseases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NOS III expression and neuritic sprouting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double label immunohistochemical staining studies
Number of subjects: 0
Study: 7873952

Group type: EXPERIMENTAL
Intervention: Problem solving treatment
Number of subjects: 91

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 2144205

Group type: EXPERIMENTAL
Intervention: Zoladex and flutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 0
Study: 797086

Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (EACA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (transurethral surgery)
Number of subjects: 40
Study: 31621523

Group type: EXPERIMENTAL
Intervention: EpxDiabetes intervention group
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 30905242

Group type: EXPERIMENTAL
Intervention: 0.05% NaF mouth rinse used at bedtime in combination with 0.22% NaF dentifrice 2 times/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.1% NaF brush-on gel used at bedtime in combination with 0.22% NaF dentifrice 2 times/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.22% NaF dentifrice used 2 times/day
Number of subjects: 12
Study: 28092973

Group type: EXPERIMENTAL
Intervention: PHCTR1 polymorphism
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: WDR12 polymorphism
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: GRS 18
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: ADAMTS7 and LPA polymorphisms
Number of subjects: 1345
Study: 26219154

Group type: EXPERIMENTAL
Intervention: Manual Vacuum Aspiration (MVA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional metal uterine curettage
Number of subjects: 0
Study: 23942177

Group type: EXPERIMENTAL
Intervention: Low‐fat vegan diet and weekly group meetings (Intervention)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Usual diet (Control)
Number of subjects: 292
Study: 21872918

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 610

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 610
Study: 19834016

Group type: EXPERIMENTAL
Intervention: Tight control (target 70 to 110 mg/dL)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Loose control (target 70 to 200 mg/dL)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual care (target 70 to 300 mg/dL)
Number of subjects: 74
Study: 17452068

Group type: EXPERIMENTAL
Intervention: M-AID mobile phone application
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (no mobile phone support)
Number of subjects: 119
Study: 12067330

Group type: EXPERIMENTAL
Intervention: IgM anti-GM1 antibodies in patients with PD (detection via ELISA, initial dilution 1:800, positive at absorbance > 0.05)
Number of subjects: 147

Group type: COMPARATOR
Intervention: IgM anti-GM1 antibodies in normal controls (detection via ELISA, initial dilution 1:800, positive at absorbance > 0.05)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: IgG anti-GM1 antibodies in patients with PD (detection via ELISA, initial dilution 1:200, positive at absorbance > 0.1)
Number of subjects: 147

Group type: COMPARATOR
Intervention: IgG anti-GM1 antibodies in normal controls (detection via ELISA, initial dilution 1:200, positive at absorbance > 0.1)
Number of subjects: 147
Study: 9486993

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 470

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 470
Study: 8536896

Group type: EXPERIMENTAL
Intervention: C1 inhibitor
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2244564

Group type: EXPERIMENTAL
Intervention: pindolol (ISA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: propranolol (non‐ISA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 681309

Group type: EXPERIMENTAL
Intervention: Halazepam
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 30216237

Group type: EXPERIMENTAL
Intervention: Low-amount, low-intensity exercise (LALI)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: High-amount, low-intensity exercise (HALI)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: High-amount, high-intensity exercise (HAHI)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control
Number of subjects: 181
Study: 27542442

Group type: EXPERIMENTAL
Intervention: CBT+NRT+CM
Number of subjects: 0

Group type: COMPARATOR
Intervention: CBT+NRT
Number of subjects: 0